Anticipating HCP prescribing behavior pre-diagnosis: PulsePoint's approach to rare disease omnichannel marketing efficiency

In rare diseases, the most critical prescribing decisions often begin before a formal diagnosis, yet traditional claims-based targeting activates 30+ days too late. PulsePoint helped a pharmaceutical brand move earlier in the clinical journey by identifying and engaging high-probability prescribers when treatment considerations are actively forming Using a predictive, multi-signal approach, PulsePoint combined real-time digital engagement, clinical activity, and brand interaction data to continuously surface the right HCPs at the right moment. Powered by PulsePoint’s HCP Explorer, HCP365, and Life, this connected omnichannel strategy enables more precise targeting during narrow, high-impact windows. The result was engagement with HCPs at least 35 days and in some cases more than 60 days earlier, 5–8x more efficient media spend, and growth in net-new prescribers. See how you can replicate these results for your brand.